ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
Phase 1
- Conditions
- Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.MedDRA version: 22.0Level: PTClassification code: 10029547Term: Non-Hodgkin's lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10000845Term: Acute lymphoblastic leukemia Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10042945Term: Systemic lupus erythematosus Class: 100000004859Therapeutic area: Diseases [C] - Immune System Diseases [C20]Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-511684-28-00
- Lead Sponsor
- Autolus Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 111
Inclusion Criteria
Patients must have received an AUTO CAR T cell therapy on a previous treatment study., Patients must have provided informed consent for long-term follow-up study prior to participation., Patients must be able to comply with the study requirements.
Exclusion Criteria
There are no exclusion criteria for this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method